Literature DB >> 32036608

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Matthew Dysthe1,2, Robin Parihar3,4.   

Abstract

Myeloid-derived suppressor cells (MDSCs) represent a heterogenous population of immature myeloid cells capable of modulating immune responses. In the context of cancer, MDSCs are abnormally produced and recruited to the tumor microenvironment (TME) to aid in the establishment of an immunosuppressive TME that facilitates tumor escape. Additionally, MDSCs contribute to non-immunologic aspects of tumor biology, including tumor angiogenesis and metastasis. The clinical significance of MDSCs has recently been appreciated as numerous studies have suggested a correlation between circulating and intratumoral MDSC frequencies and tumor stage, progression, and treatment resistance. In this chapter, we review MDSC characterization, development, expansion, and mechanisms that facilitate immunosuppression and tumor progression. Furthermore, we highlight studies demonstrating the clinical significance of MDSCs in various disease states in addition to strategies that modulate various aspects of MDSC biology for therapeutic gain.

Entities:  

Keywords:  Angiogenesis; Arginase-1; Autoimmunity; Cancer; Immunosuppression; Metastasis; Myeloid-derived suppressor cells (MDSC); Myelopoiesis; Regulatory T cells (Treg); S100A9; STAT3; Solid tumor; Therapeutic strategies; Therapy resistance; Transforming growth factor (TGF)-β; Tumor microenvironment (TME)

Mesh:

Year:  2020        PMID: 32036608     DOI: 10.1007/978-3-030-35723-8_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  42 in total

1.  Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition.

Authors:  Chandra C Ghosh; Kara R Heatherton; Kyle P O' Connell; Ian S Alexander; Deborah A Greer; Jason LaPorte; Prajna Guha; Bryan F Cox; Steven C Katz
Journal:  Cancer Gene Ther       Date:  2022-06-14       Impact factor: 5.987

2.  Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.

Authors:  Binita Chakraborty; Jovita Byemerwa; Jonathan Shepherd; Corinne N Haines; Robert Baldi; Weida Gong; Wen Liu; Debarati Mukherjee; Sandeep Artham; Felicia Lim; Yeeun Bae; Olivia Brueckner; Kendall Tavares; Suzanne E Wardell; Brent A Hanks; Charles M Perou; Ching-Yi Chang; Donald P McDonnell
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 14.808

Review 3.  Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.

Authors:  Qing Li; Ming Xiang
Journal:  Acta Pharmacol Sin       Date:  2021-09-24       Impact factor: 7.169

Review 4.  CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients.

Authors:  Fatih M Uckun; Justin Watts
Journal:  Front Aging       Date:  2021-09-27

Review 5.  VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment.

Authors:  Yueshui Zhao; Sipeng Guo; Jian Deng; Jing Shen; Fukuan Du; Xu Wu; Yu Chen; Mingxing Li; Meijuan Chen; Xiaobing Li; Wanping Li; Li Gu; Yuhong Sun; Qinglian Wen; Jing Li; Zhangang Xiao
Journal:  Int J Biol Sci       Date:  2022-05-29       Impact factor: 10.750

6.  Reducing Stress PERKs up Anti-tumor Immunity.

Authors:  Marie-Eve Charbonneau; Mary X D O'Riordan
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

7.  Germline mutations and blood malignancy (Review).

Authors:  Yuping Gong; Jili Deng; Xia Wu
Journal:  Oncol Rep       Date:  2020-11-11       Impact factor: 3.906

Review 8.  Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies.

Authors:  Alejandro Olivares-Hernández; Luis Figuero-Pérez; Eduardo Terán-Brage; Álvaro López-Gutiérrez; Álvaro Tamayo Velasco; Rogelio González Sarmiento; Juan Jesús Cruz-Hernández; José Pablo Miramontes-González
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

9.  TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host.

Authors:  Ge Song; Yue Zhang; Jie Tian; Jie Ma; Kai Yin; Huaxi Xu; Shengjun Wang
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 10.  The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.

Authors:  Evangelos Koustas; Panagiotis Sarantis; Athanasios G Papavassiliou; Michalis V Karamouzis
Journal:  Biomolecules       Date:  2020-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.